Tags

Type your tag names separated by a space and hit enter

Efficacy and safety of factor VIII/von Willebrand's factor concentrate (Haemate-P) in preventing bleeding during surgery or invasive procedures in patients with von Willebrand disease.
Haematologica. 2003 Nov; 88(11):1279-83.H

Abstract

BACKGROUND AND OBJECTIVES

To evaluate the efficacy and safety of the factor VIII/von Willebrand factor concentrate Haemate-P as replacement therapy in patients with von Willebrand's disease (VWD) undergoing surgical or invasive procedures.

DESIGN AND METHODS

Between January 1996 and October 2002, 26 patients (12 males and 14 females, median age 41.5 years, range 9-80 years), followed at three Italian Hemophilia Centers (Trento, Verona and Parma), with VWD type 1 (19 cases) and VWD type 2B (7 cases), underwent 43 surgical or invasive procedures: major surgery (14 cases), minor surgery (11 cases), dental extractions (11 cases), invasive diagnostic procedures (7 cases). Replacement therapy with factor VIII/von Willebrand factor concentrate (Haemate-P) was administered in the surgical setting as perioperative prophylaxis against excessive bleeding.

RESULTS

The mean total dose (range) of Haemate-P used for major surgery was 284.1 IU VWF:RCo/kg (range 125.0-976.4), for minor surgery it was 120.8 IU VWF:RCo/kg (range 42.9-173.3), for dental extractions it was 38.4 IU VWF:RCo/kg (range 23.5-100.0) and for invasive procedures it was 87.3 VWF:RCo/kg (range 27.3-160.0). We recorded one bleeding episode 3 days after multiple dental extractions in a patient with severe periodontal disease; this bleeding was controlled with 2 further administrations of concentrate. We did not observe thrombotic episodes or other side effects following infusion of the concentrate.

INTERPRETATION AND CONCLUSIONS

In conclusion, Haemate-P was effective and safe in preventing excessive bleeding after major and minor surgery or invasive procedures in VWD patients.

Authors+Show Affiliations

Servizio di Immunoematologia e Trasfusione, Centro Emofilia, Azienda Ospedaliera di Verona,Verona, Italy. mfranchini@mail.univr.itNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study

Language

eng

PubMed ID

14607757

Citation

Franchini, Massimo, et al. "Efficacy and Safety of Factor VIII/von Willebrand's Factor Concentrate (Haemate-P) in Preventing Bleeding During Surgery or Invasive Procedures in Patients With Von Willebrand Disease." Haematologica, vol. 88, no. 11, 2003, pp. 1279-83.
Franchini M, Rossetti G, Tagliaferri A, et al. Efficacy and safety of factor VIII/von Willebrand's factor concentrate (Haemate-P) in preventing bleeding during surgery or invasive procedures in patients with von Willebrand disease. Haematologica. 2003;88(11):1279-83.
Franchini, M., Rossetti, G., Tagliaferri, A., Pattacini, C., Pozzoli, D., Lippi, G., Manzato, F., Bertuzzo, D., & Gandini, G. (2003). Efficacy and safety of factor VIII/von Willebrand's factor concentrate (Haemate-P) in preventing bleeding during surgery or invasive procedures in patients with von Willebrand disease. Haematologica, 88(11), 1279-83.
Franchini M, et al. Efficacy and Safety of Factor VIII/von Willebrand's Factor Concentrate (Haemate-P) in Preventing Bleeding During Surgery or Invasive Procedures in Patients With Von Willebrand Disease. Haematologica. 2003;88(11):1279-83. PubMed PMID: 14607757.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Efficacy and safety of factor VIII/von Willebrand's factor concentrate (Haemate-P) in preventing bleeding during surgery or invasive procedures in patients with von Willebrand disease. AU - Franchini,Massimo, AU - Rossetti,Gina, AU - Tagliaferri,Annarita, AU - Pattacini,Corrado, AU - Pozzoli,Donatella, AU - Lippi,Giuseppe, AU - Manzato,Franco, AU - Bertuzzo,Daniela, AU - Gandini,Giorgio, PY - 2003/11/11/pubmed PY - 2004/2/26/medline PY - 2003/11/11/entrez SP - 1279 EP - 83 JF - Haematologica JO - Haematologica VL - 88 IS - 11 N2 - BACKGROUND AND OBJECTIVES: To evaluate the efficacy and safety of the factor VIII/von Willebrand factor concentrate Haemate-P as replacement therapy in patients with von Willebrand's disease (VWD) undergoing surgical or invasive procedures. DESIGN AND METHODS: Between January 1996 and October 2002, 26 patients (12 males and 14 females, median age 41.5 years, range 9-80 years), followed at three Italian Hemophilia Centers (Trento, Verona and Parma), with VWD type 1 (19 cases) and VWD type 2B (7 cases), underwent 43 surgical or invasive procedures: major surgery (14 cases), minor surgery (11 cases), dental extractions (11 cases), invasive diagnostic procedures (7 cases). Replacement therapy with factor VIII/von Willebrand factor concentrate (Haemate-P) was administered in the surgical setting as perioperative prophylaxis against excessive bleeding. RESULTS: The mean total dose (range) of Haemate-P used for major surgery was 284.1 IU VWF:RCo/kg (range 125.0-976.4), for minor surgery it was 120.8 IU VWF:RCo/kg (range 42.9-173.3), for dental extractions it was 38.4 IU VWF:RCo/kg (range 23.5-100.0) and for invasive procedures it was 87.3 VWF:RCo/kg (range 27.3-160.0). We recorded one bleeding episode 3 days after multiple dental extractions in a patient with severe periodontal disease; this bleeding was controlled with 2 further administrations of concentrate. We did not observe thrombotic episodes or other side effects following infusion of the concentrate. INTERPRETATION AND CONCLUSIONS: In conclusion, Haemate-P was effective and safe in preventing excessive bleeding after major and minor surgery or invasive procedures in VWD patients. SN - 1592-8721 UR - https://www.unboundmedicine.com/medline/citation/14607757/Efficacy_and_safety_of_factor_VIII/von_Willebrand's_factor_concentrate__Haemate_P__in_preventing_bleeding_during_surgery_or_invasive_procedures_in_patients_with_von_Willebrand_disease_ L2 - http://www.haematologica.org/cgi/pmidlookup?view=long&pmid=14607757 DB - PRIME DP - Unbound Medicine ER -